June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16 doi:10.5837/bjc.2016.s01
Yassir Javaid
Introduction Heart failure, if left untreated, has a worse prognosis than the majority of cancers. Yet with the best possible treatment − most of which can and possibly should be delivered in primary care − the one-year mortality can be as low as 10%. Earlier articles in this supplement have described how beta blockers, angiotensin-converting enzyme (ACE) inhibitors and mineralocorticoid receptor antagonists (MRAs) offer significant incremental survival benefits to patients with heart failure and reduced ejection fraction (HFREF) that can be further augmented by device therapy. Consider: an implantable cardioverter defibrillator (ICD) in
June 2016 Br J Cardiol 2016;23:51
BJCardio Staff
The 2016 guidelines include for the first time the new drug sacubitril/valsartan (previously known as LCZ696). This is the first drug in the class of angiotensin receptor neprilysin inhibitors (ARNIs) and was shown in the PARADIGM-HF trial to be superior to the angiotensin-converting enzyme (ACE) inhibitor enalapril for reducing the risk of death and hospitalisation in patients with heart failure with reduced ejection fraction (HFREF) who met strict inclusion and exclusion criteria. Professor Piotr Ponikowski (Chairperson of the ESC Guidelines Task Force), said: “The issue of how to include LCZ696 in the treatment algorithm generated a lot
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits